|
ИСТИНА |
Войти в систему Регистрация |
ИСТИНА ПсковГУ |
||
Tailored iron oxide nanoparticles for biomedical applications: Hydroxyethyl starch coating enhances endothelial biocompatibilityстатья
Информация о цитировании статьи получена из
Scopus
Статья опубликована в журнале из списка Web of Science и/или Scopus
Дата последнего поиска статьи во внешних источниках: 23 января 2026 г.
- Авторы: Thrapsanioti L.N., Kuskov A.N., Berdiaki A., Luss A.L., Vlaskina E.R., Ivanova A.V., Abakumov M.A., Marmara M., Plexousaki K., Tsatsakis A., Nikitovic D.
- Журнал: Nanomedicine: Nanotechnology, Biology, and Medicine
- Том: 71
- Год издания: 2026
- Издательство: Elsevier BV
- Местоположение издательства: Netherlands
- Номер статьи: 102880
- DOI: 10.1016/j.nano.2025.102880
- Аннотация: Iron oxide nanoparticles (IONPs) offer promise for drug delivery and imaging, but their vascular safety requires thorough evaluation. Hydroxyethyl starch (HES) is a clinically used, biocompatible polysaccharide with potential as a nanoparticle coating to improve vascular safety. We synthesized novel hydroxyethyl starch-coated IONPs (IONPs@HES) and assessed their properties and effects on human microvascular endothelial cells (HMEC-1) under basal and inflammatory conditions. IONPs@HES showed magnetite cores, near-neutral charge, and reduced magnetic saturation, supporting biocompatibility. They were efficiently internalized without affecting viability or proliferation (20–500 μg/mL) and did not increase LPS-induced ICAM-1 expression. Autophagic activity, assessed by LC3 immunofluorescence and Cyto-ID flow cytometry, remained unchanged, suggesting preserved autophagic homeostasis. A modest increase in phosphorylated caveolin-1 (p-CAV1) was observed, with no enhancement under LPS stimulation. Co-treatment with indomethacin showed no additive toxicity. These findings support IONPs@HES as a biocompatible nanoplatform suitable for vascular-targeted cancer therapy, meriting further in vivo validation.
- Добавил в систему: Кусков Андрей Николаевич